Emoksipin-Acti - instructions for use, dose, side effects, contraindications

Composition for:	1 ml	100 ml
active substance:
methyl ethylpyridinol hydrochloride	5.0 mg	500 mg
Excipients:
sodium chloride	7.3 mg	730 mg
water for injections	up to 1 ml	up to 100 ml

Physico-chemical characteristics:

theoretical osmolarity	307 mOsmol / l
pH	from 4.0 to 6.0

Description:

A clear, colorless or light yellow solution

Pharmacotherapeutic group:Antioxidant

ATX: & nbsp

S.01.X.A Other drugs for the treatment of eye diseases

Pharmacodynamics:

Emoksipin-Acti has a beneficial effect on the blood coagulation system: inhibits platelet aggregation, reduces the overall coagulation index, and prolongs the coagulation time. Stabilizes the membranes of cells of blood vessels and erythrocytes, increases the resistance of red blood cells to mechanical trauma and hemolysis. It has angioprotective properties. Improves microcirculation.

Effectively inhibits free radical oxidation of lipids of biomembranes, increases the activity of antioxidant enzymes. Stabilizes cytochrome P-450, has an antitoxic effect. In extreme situations, accompanied by increased lipid peroxidation and hypoxia, it optimizes bioenergetic processes.

Increases brain resistance to hypoxia and ischemia. With violations of cerebral circulation (ischemic and hemorrhagic) contributes to the correction of vegetative dysfunctions, facilitates the restoration of integrative activity of the brain, improves mnestic functions.

Has hypolipidemic action, reduces the synthesis of triglycerides.

The drug has a pronounced cardioprotective effect. Expands coronary vessels, reduces ischemic damage to the myocardium. With myocardial infarction limits the magnitude of the focus of necrosis, accelerates reparative processes, contributes to the normalization of myocardial metabolism. Has a beneficial effect on the clinical course of myocardial infarction, reducing the incidence of acute heart failure. Promotes regulation of the oxidation-reduction system in case of circulatory failure.

Pharmacokinetics:

When administered intravenously at a dose of 10 mg / kg, a low half-life of T_1/2- 18 min, which indicates a high rate of elimination of the drug from the blood. The value of the elimination constant is 0.041 min; total clearance - 214.8 ml / min; apparent volume of distribution V_each. - 5.2 liters.The drug quickly penetrates into the organs and tissues, where it is deposited and metabolized. There were 5 metabolites of the preparation, represented by dealkylated and conjugated products of its transformation. Metabolites of the drug Emoksipin-Akti are excreted by the kidneys. In significant quantities, 2-ethyl-6-methyl-3-hydroxypyridine phosphate is found in the liver.

In pathological conditions, for example, in the case of coronary occlusion, the pharmacokinetics of the drug vary. Decreased rate of excretion, resulting in increased bioavailability of the drug. The time of its being in the circulatory bed increases, which may be due to the reverse receipt of the drug from the depot, including from the ischemic myocardium.

Indications:

As part of complex therapy:

In neurology and neurosurgery: hemorrhagic stroke in the recovery period, ischemic stroke in the internal carotid artery and in the vertebrobasilar system, transient cerebral circulatory disorders, chronic cerebral circulatory insufficiency, craniocerebral trauma accompanied by brain contusions; postoperative period in patients with craniocerebral trauma,Operated for epi-, subdural and intracerebral hematomas, combined with bruises of the brain.

In cardiology: acute myocardial infarction, prevention of "reperfusion syndrome", unstable angina.

Contraindications:

Increased individual sensitivity to the drug, children under 18 years.

Pregnancy and the period of breastfeeding.

Carefully:

Be wary appoint patients with allergic reactions in the history.

Pregnancy and lactation:

Use during pregnancy and during breastfeeding is not allowed.

Dosing and Administration:

In Neurology and Neurosurgery solution of the drug Emoksipin-Akti for infusion is used intravenously drip in a daily dose of 10 mg / kg (2 ml / kg) for 10-12 days. Enter at a speed of 20-30 drops per minute.

In cardiology begin with an intravenous drip (20-40 drops per minute) introducing 120-180 ml of the drug (600-900 mg of the drug) 1-3 times a day for 5-15 days, depending on the course of the disease.

When treating the drug should monitor blood pressure and the functional state of coagulating and anticoagulating blood systems.

Side effects:

Allergic reactions: skin rashes, itching, congestion, erythema.

From the cardiovascular system: increased blood pressure, pain in the heart.

From the nervous system: short-term agitation, drowsiness, headache.

From the gastrointestinal tract: nausea, discomfort in the stomach area (in persons with chronic disorders of the digestive system).

Other: local reactions in the field of administration - pain, burning, itching, hyperemia.

Overdose:

Overdose may increase the severity of the side effects of the drug.

Symptoms: increase in blood pressure, agitation, and somnolence, headache, chest pain, nausea, discomfort in the epigastric region. There may be a clotting disorder.

Treatment: symptomatic, including the appointment of antihypertensive drugs under the control of blood pressure. There is no specific antidote.

Interaction:

Do not mix Emoksipin Akti with other drugs (pharmaceutically incompatible with other drugs).

α-Tocopherol acetate potentiates the antioxidant effect of the drug.

Special instructions:

Treatment with the drug should be carried out under the control of blood pressure and blood coagulability.

Effect on the ability to drive transp. cf. and fur:

It is necessary to refrain from managing vehicles and other moving mechanisms, as well as to be cautious in carrying out potentially dangerous activities that require an increased concentration of attention and speed of psychomotor reactions.

Form release / dosage:

Solution for infusion, 5 mg / ml.

Packaging:

To 100 ml in containers polymeric (polyvinyl chloride) for infusion solutions. Each polymer container, together with a medical instruction, is placed in a separate transparent bag made of high pressure polyethylene.

For hospitals: each polymeric container is placed in a transparent plastic bag and placed in boxes of 100 corrugated cardboard boxes along with instructions for medical use in an amount corresponding to the number of polymer containers.

Storage conditions:

Store in a dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

2 years.

Do not use after the expiration date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:LP-004024

Date of registration:22.12.2016

Expiration Date:22.12.2021

The owner of the registration certificate:Aktifarm, OOOAktifarm, OOO Russia

Manufacturer: & nbsp

"Belarusian-Dutch joint venture LLC" FARMLEND "" Republic of Belarus

Information update date: & nbsp25.01.2017

Illustrated instructions

Instructions

Emoxipine-Acti (Emoxipine-Akti)